Monday, October 26, 2026

MP Materials targets 10,000-tonne magnet output by 2028, tenfold scale-up from current capacity

MP Materials plans to commission its 10X magnet facility in 2028, expanding annual production from 1,000 to 10,000 metric tonnes. The scale-up addresses rare earth supply chain bottlenecks as U.S. manufacturers reduce China dependence. Increased magnet availability could pressure neodymium-praseodymium oxide prices while boosting domestic EV and defense production capacity.

MP Materials targets 10,000-tonne magnet output by 2028, tenfold scale-up from current capacity
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

MP Materials aims to commission its 10X magnet manufacturing facility in 2028, scaling annual output from 1,000 to 10,000 metric tonnes. The Fort Worth, Texas expansion represents the largest planned increase in Western rare earth magnet capacity this decade.

The company currently operates the only integrated rare earth mining and processing site in North America at Mountain Pass, California. Current production serves niche defense and industrial applications. The tenfold increase targets electric vehicle motors, wind turbines, and military systems.

Rare earth permanent magnets require neodymium, praseodymium, dysprosium, and terbium—elements where China controls 90% of global refining capacity. MP Materials' vertical integration from mine to magnet reduces supply chain exposure. The company extracts concentrate at Mountain Pass, processes oxides domestically, and will manufacture finished magnets in-house by 2028.

Market implications split across commodity and equity channels. Increased magnet supply could pressure neodymium-praseodymium oxide prices, which spiked to $160,000 per tonne in 2022 before settling near $50,000. Sustained production at 10,000 tonnes annually equals roughly 15% of current global magnet output, sufficient to move pricing if Chinese producers don't curtail supply.

Equity traders are watching rare earth miners and magnet consumers. Lynas Rare Earths and Energy Fuels compete in Western supply chains. Tesla, Rivian, and General Motors face magnet procurement constraints that limit EV scaling. Defense contractors Lockheed Martin and Raytheon depend on magnets for guidance systems and actuators.

The 2028 timeline carries execution risk. Magnet manufacturing requires sintering furnaces, coating lines, and quality control systems that have caused delays at other facilities. MP Materials hasn't disclosed capital expenditure for the 10X buildout, though comparable projects run $400-600 million.

Commissioning aligns with Inflation Reduction Act incentives for domestic EV supply chains. Automakers securing U.S.-sourced magnets gain tax credit eligibility, creating offtake demand before the facility starts. Forward contracts could lock pricing and validate the investment case ahead of first production.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]News articleYahoo Finance· January 13, 2026
    Will the US’ onshoring strategy remove China’s chokehold on REEs?

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com